Cardioversion and risk of adverse events with dabigatran versus warfarin - A nationwide cohort study

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Pallisgaard, Jannik Langtved ^a,b   Lindhardt, Tommi Bo ^a,b   Hansen, Morten Lock ^a,c   Schjerning, Anne Marie ^a   Olesen, Jonas Bjerring ^a   Staerk, Laila ^a,b   Torp Pedersen, Christian ^d   Gislason, Gunnar Hilmar ^a,b,e,f  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f The Danish Heart Foundation   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPLICATION; FOLLOW UP; HOSPITAL MANAGEMENT; INCIDENCE; REGISTER; RISK; THROMBOEMBOLISM; TIME FACTOR;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; DENMARK; FEMALE; FOLLOW-UP STUDIES; HOSPITAL ADMINISTRATION; HUMANS; INCIDENCE; MALE; REGISTRIES; RISK; THROMBOEMBOLISM; TIME FACTORS; WARFARIN;

EID: 84949807231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141377     Document Type: Article

References (15)

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2014;64:e1-e76.
2. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D. C. electrical conversion of atrial fibrillation. The American Journal of Cardiology. 1969;23:208-216.
3. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. Journal of the American College of Cardiology. 1992;19:851-855.
4. Klein AL, Grimm RA, Jasper SE, Murray RD, Apperson-Hansen C, Lieber EA, et al. ACUTE Steering and Publications Committee for the ACUTE Investigators. Efficacy of transesophageal echocardiographyguided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. Am Heart J. 2006;151:380-389.
5. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, et al. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation. 2004;109:997-1003.
6. Camm AJ, Lip GYH, Caterina RD, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillationDeveloped with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
7. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961-970.
8. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion. Circulation. 2011;123:131-136.
9. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
10. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38-41.
11. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ [Internet]. 2011 [cited 2013 Jun. 13]; 342. Available from: http://www.ncbi.nlm. nih.gov/pmc/articles/PMC3031123
12. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma C-S, Heuzey J-Y Le, et al., on behalf of the XVeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346-3355.
13. Flaker G, Lopes RD, Khatib SM Al-, Hermosillo AG, Hohnloser SH, Tinga B, et al. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation: Insights From the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). Journal of the American College of Cardiology. 2014;63:1082-1087.
14. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial Fibrillation Begets Atrial Fibrillation A Study in Awake Chronically Instrumented Goats. Circulation. 1995;92:1954-1968.
15. Asher CR, Klein AL. The ACUTE trial. Transesophageal echocardiography to guide electrical cardioversion in atrial fibrillation. Assessment of Cardioversion Using Transesophageal Echocardiography. Cleveland Clinic Journal of Medicine. 2002;69:713-718.